Jubilant Ingrevia posts best quarterly revenue in 14 quarters, flags growth acceleration ahead
A solid quarter with strong execution, but CDMO ramp-up and agro recovery are critical for sustained 20% EBITDA growth.
What management said
- Q4 revenue at ₹1,179 crore, up 12% YoY, highest in 14 quarters.
- Management expects sequential growth from Q1 FY27 across segments.
- CDMO pipeline includes 100+ opportunities worth ₹3,500 crore potential.
- Specialty chemicals EBITDA margin at 27% for six consecutive quarters.
- Acquired Remedex to strengthen human nutrition premix portfolio.
The brief
Revenue hit ₹1,179 crore. Up 12% year on year. That was the best quarter in 14. EBITDA rose 11% to ₹172 crore, while PAT grew 17% to ₹86 crore, reflecting strong execution despite Middle East disruptions that firmed up input costs. Specialty chemicals revenue reached a record ₹516 crore. EBITDA margins held at 27% for six consecutive quarters. Nutrition revenue climbed 21% to ₹230 crore, driven by volume recovery in niacinamide and choline, with the addition of Remedex for human nutrition. The CDMO pipeline now has 100-plus opportunities worth ₹3,500 crore. A large agro contract started shipping in March. Management expects sequential growth from Q1 FY27 and reiterated its target of at least 20% EBITDA growth, with capex guided at ₹400-500 crore for the year. The quarter shows improving fundamentals. Delivery on CDMO contracts and agro recovery will determine if the acceleration is sustainable.
In their words
“Our Q4FY26 run rate EBITDA is 70% plus higher than Q4FY24 EBITDA signaling the pace of improvement we could showcase in last two years.”— Deepak Jain — CEO and Managing Director
“We are hoping to accelerate our growth starting with Q1FY27 itself.”— Deepak Jain — CEO and Managing Director
Summarised from the Jubilant Ingrevia Ltd Q4 2026 earnings-call transcript. View transcript.